BACKGROUND: Glucagon and glucagon-like peptide-1 (GLP-1) are evolutionarily related anorectic hormones. Glucagon also increases energy expenditure. The combination of glucagon and GLP-1 could cause weight loss through a simultaneous reduction in food intake and increased energy expenditure. However, the effect of combined administration of glucagon and GLP-1 on food intake and neuronal activation has not previously been studied. Furthermore, the effect of glucagon on neuronal activation in appetite regulating centres has not been assessed. Characterisation of the effects of glucagon when administered singly and in combination with GLP-1 on neuronal activation will be important for determining the mechanism of action of related potential antiobesity therapies. OBJECTIVES: To investigate the effects of peripherally administered GLP-1 and glucagon on food intake, neuronal activation and blood glucose in mice when administered individually and in combination. METHODOLOGY: Food intake, blood glucose and c-fos expression in the hypothalamus, amygdala and brainstem were measured in response to GLP-1 and glucagon, alone and in combination. RESULTS: Peripherally administered GLP-1 and glucagon decreased food intake and increased c-fos expression in the brainstem and amygdala. Doses of GLP-1 and glucagon that individually did not significantly affect feeding, in combination were anorectic and stimulated neuronal activation in the area postrema (AP) and central nucleus of the amygdala. Combined administration of GLP-1 and glucagon prevented the acute hyperglycemic effect of glucagon alone. CONCLUSION: Anorectic doses of glucagon and GLP-1 induced similar patterns of c-fos expression. Combined administration of low dose GLP-1 and glucagon inhibited food intake and induced c-fos expression in the AP and amygdala. The combination of both hormones may offer the opportunity to utilise the beneficial effects of reduced food intake and increased energy expenditure, and may therefore be a potential treatment for obesity.
INTRODUCTION
Obesity is an increasing problem worldwide yet current pharmaceutical treatments only produce modest weight loss, which is rarely sustained. Glucagon and glucagon-like peptide-1 (GLP-1) reduce food intake and the combination of glucagon and GLP-1 agonists may be useful in the treatment of obesity. Our aim was to establish whether glucagon and GLP-1, while evolutionarily similar, caused c-fos activation in distinct areas within the brain to exert an anorectic effect.
Glucagon and GLP-1 are both products of the preproglucagon gene. GLP-1 is an incretin hormone that enhances glucosemediated insulin release and inhibits glucagon secretion. GLP-1 receptor agonists are licensed for the treatment of type 2 diabetes mellitus. 1 In addition to improving glycaemia, 2 they reduce appetite, driving modest weight loss.
Although glucagon opposes the action of GLP-1 on glucose homoeostasis, both hormones share an anorectic effect. Peripherally administered glucagon decreases food intake and body weight in both rodents and humans. [3] [4] [5] [6] [7] Conversely, administration of glucagon antibodies increases meal size in rats. 4, 8 Glucagon also increases energy expenditure in rodents and humans. [9] [10] [11] Therefore, the combination of glucagon and GLP-1 could be of therapeutic value in obesity through a simultaneous reduction in food intake and increased energy expenditure, while maintaining normal glucose levels.
Historically, the deleterious effect of unopposed glucagon on glucose homoeostasis has discouraged study of the mechanism, by which glucagon reduces appetite. In particular, the pattern of neuronal activation in the central nervous system after peripheral administration of glucagon has not been described. The anorectic effects of GLP-1 and glucagon are attenuated by vagotomy or by ablation of brainstem-hypothalamic pathways, suggesting a peripheral mechanism of action mediated by the vagus nerve. 3, [12] [13] [14] [15] [16] To investigate the relationship between the anorectic effects of glucagon and GLP-1, we have studied their individual and combined effects on acute food intake in mice. We used c-fos immunohistochemistry in the hypothalamus, brainstem and 1 amygdala, to characterise neuronal activation following their administration. Finally we examined the effects of acute administration of glucagon and GLP-1 individually and in combination on blood glucose in mice. Our primary aims were to determine whether these two hormones activate similar centres in the brain and whether lower doses of each individual hormone could be administered in combination to cause a significant reduction in food intake. Additionally, we wished to determine whether combined GLP-1 and glucagon administration could prevent any hyperglycemic effect of glucagon acutely, which is important if agonists at the GLP-1 and glucagon receptors are to be developed as treatments for obese patients with type 2 diabetes.
MATERIALS AND METHODS Materials
Human sequence glucagon and GLP-1(7-37) were purchased from Bachem Ltd (Merseyside, UK).
C57BL/6 mice
Adult male C57BL/6 mice (Charles River, Margate, UK) were maintained under controlled temperature (21-23 1C) and lighting (12 : 12 h light-dark cycle, lights on at 0700 hours). Mice in feeding studies (body weight 25-30 g) and glucose measurements (body weight 26-37 g) were housed in individual cages, but those in immunohistochemistry studies (weight 23-28 g) were group-housed. All mice had ad libitum access to water and RM1 diet (Special Diet Services, Witham, UK) unless otherwise stated. They were regularly handled and acclimatised to subcutaneous (s/c) injections to reduce non-specific stress during studies. All animal procedures undertaken were approved by the British Home Office Animal (Scientific Procedures) Act 1986 (Project Licence 70/7236).
Acute feeding studies in mice
Experiments were carried out during the early light phase (0800-1000) after fasting from 1600 the preceding day. Randomisation of treatment allocation was stratified by body weight. All studies used a betweensubjects design. All mice were injected (maximum volume 50 ml) within a single 30 min period, with individual injection times noted, then returned to their home cages with a known amount of food. Food was reweighed at 30, 90 and 180 min post injection. On the basis of previous studies, in the first set of experiments, mice received s/c glucagon at 30, 100, 300, 500 or 750 nmol kg À 1 , or vehicle, and in the second study, mice received s/c GLP-1 at 3, 10, 30, 50, 100 or 600 nmol kg À 1 , or vehicle (n ¼ 6). On the basis of the results of the dose response studies, in a third study, each mouse received two s/c injections, one of 30 nmol kg À 1 glucagon or vehicle, and the other of 10 nmol kg À 1 GLP-1 or vehicle, in quick succession (n ¼ 6). In all studies, the vehicle was 0.9% saline.
c-fos immunohistochemistry studies in mice
Animal conditions and tissue preparation. The mice were handled daily and acclimatised to study conditions by fasting overnight on two occasions and receiving three s/c injections of saline over the 2 weeks before each study. Experiments were carried out during the early light phase (0800-1000 hours) after fasting from 1600 the preceding day. Mice (n ¼ 5-6 per group) were injected s/c (maximum volume 0.05 ml) and immediately returned to their cages. Ninety minutes later, they were anaesthetised with intraperitoneal pentobarbitone (Euthatal, Merial Animal Health Ltd. Harlow, UK) before decapitation. Whole-brains were rapidly removed and immediately placed in 4% formaldehyde in 0.01 M phosphate-buffered saline for 24 h, then in 40% sucrose solution for 3-4 days. They were then frozen in liquid nitrogen-cooled isopentane before storage at À 80 1C. Coronal sections through the brainstem and hypothalamus were cut at 40 mm using a sled microtome. Free-floating sections were stored in antifreeze (0.01 M phosphate-buffered saline, 20% glycerol, 30% ethylene glycol) at À 20 1C until staining.
c-fos immunohistochemistry. This was performed as previously described. 17 Briefly, free-floating sections were incubated with 1:20 000 rabbit anti c-fos antibody (Merck Chemicals Ltd. Nottingham, UK) overnight, followed by a 2 h incubation in secondary antibody (1:400 biotinylated antirabbit ImmunoglobulinG; Vector Laboratories, Peterborough, UK), followed by a further 1 h incubation in avidin À biotin peroxidase complex solution (Vector Laboratories, UK). After washing, sections were immersed in 0.01 M phosphate-buffered saline with 1% diaminobenzedine tetrahydrochloride and 0.01% hydrogen peroxide. Sections were mounted onto polylysine-coated slides, dried and mounted in xylene. Total numbers of cell bodies positive for c-fos-like immunoreactivity were counted bilaterally from matched sections by a blinded observer in hypothalamic and brainstem nuclei known to be involved in appetite regulation and the central nucleus of the amygdala (CeA). Animals were only included in the analysis if they could be matched at all the chosen sections across a nucleus. Only darkly labelled ovalshaped nuclei were counted as c-fos positive. Regions of interest and nuclear boundaries were defined in relation to anatomical landmarks using a mouse brain atlas for guidance. 18 Data are presented as the mean and s.e.m of the mean number of c-fos positive nuclei across a nucleus. The number of matched sections counted for each nucleus in each study and their coordinates, as defined in a mouse brain atlas, 18 are given in Supplementary Table 1 .
Glucose measurement in mice
Experiments were carried out during the early light phase (0800-1000 hours) in ad libitum fed mice. Randomisation of treatment allocation was stratified by body weight. On the basis of the results of the dose response studies, each mouse received two s/c injections, one of 30 nmol kg 
Statistical analysis
Food intake and c-fos immunoreactivity in dose response studies was analysed using one-way analysis of variance (ANOVA) with Dunnett's post hoc test comparing each group with the saline control. In the combined GLP-1/glucagon feeding study and c-fos study, data were analysed using one-way ANOVA followed by the Bonferroni post hoc test. Glucose measurements were compared using two way repeated measures ANOVA with Bonferroni post test (Prism v5, GraphPad Software Inc. San Diego, CA, USA). In all cases Po0.05 was considered statistically significant.
RESULTS
The effect of anorectic doses of glucagon on food intake and c-fos immunoreactivity Glucagon reduced food intake within 30 min of administration at doses of 100 nmol kg À 1 and greater (ANOVA main effect F(5,30) ¼ 12.9, Po0.001, mean food intake: 0.56 ± 0.04 (saline) vs 0.30 ± 0.06 g (glucagon 100 nmol kg À 1 ), Po0.01 vs saline; n ¼ 6/ group; Figure 1a ). Cumulative food intake at 180 min showed no significant differences between saline and glucagon at any of the doses administered (data not shown).
Glucagon increased c-fos immunoreactivity in the area postrema (AP) at 300 nmol kg À 1 and higher doses (ANOVA main effect F(5,15) ¼ 9.7, Po0.001, mean c-fos counts: AP: 7±6 (saline) vs 99 ± 17 (glucagon 300 nmol kg À 1 ), Po0.01 vs saline, n ¼ 3-5/ group; Figures 1b and 2a and b) . In the caudal nucleus tractus solitarius (cNTS), glucagon also significantly increased c-fos immunoreactivity at 300 nmol kg À 1 and at higher doses (ANOVA main effect F(5,17) ¼ 28.8, Po0.001, mean c-fos counts: cNTS: 3 ± 1 (saline) vs 75 ± 4 (glucagon 300 nmol kg À 1 ), Po0.01 vs saline, n ¼ 3-5/group; Figures 1c and 2a þ b) . The same doses of glucagon increased c-fos immunoreactivity in the CeA, (ANOVA main effect F(5,19) ¼ 18, Po0.001, mean c-fos counts: CeA: 28 ± 8 (saline) vs 92±15 (glucagon 300 nmol kg Table 2 ).
The effect of anorectic doses of GLP-1 on food intake and c-fos immunoreactivity The lowest effective anorectic dose of GLP-1 was 30 nmol kg À 1 , which reduced food intake for up to 30 min (ANOVA main effect F(6,35) ¼ 12.6, Po0.001, mean food intake: 0.49±0.02 g (saline) vs 0.23 ± 0.03 g (30 nmol kg À 1 ), Po0.01; n ¼ 6/group; Figure 3a) . At the highest dose tested (600 nmol kg À 1 ), an anorectic effect was still observed at 90 min.
GLP-1 increased c-fos immunoreactivity in the AP at 50 nmol kg The effect of combined administration of GLP-1 and glucagon on glucose measurements On the basis of the feeding studies and c-fos immunoreactivity results, we investigated the effect of combined administration of GLP-1 and glucagon on circulating glucose levels. At a dose of 30 nmol kg À 1 , glucagon alone caused a significant rise in glucose 15 min following injection (mean glucose 7.2 ± 0.4 (saline) vs 9.2±0.4 mmol l À 1 (glucagon), Po0.001 vs saline, n ¼ 8-9/group; Figure 6 ). However, coadministration of glucagon and GLP-1 prevented the rise in glucose seen in response to glucagon alone (mean glucose 9.2 ± 0.4 (glucagon) vs 7.6 ± 0.3 mmol l À 1 (coadministered GLP-1 and glucagon), Po0.01 vs glucagon alone, n ¼ 8-9/ group; Figure 6 ). Glucose readings following GLP-1 alone (10 nmol kg À 1 ), showed no significant differences to saline controls at any time points. However, 60 min following injection, glucose levels in response to GLP-1 alone were significantly higher than glucagon alone or glucagon and GLP-1 in combination (mean glucose 7.9 ± 0.4 (GLP-1) vs 6.7 ± 0.3 mmol l À 1 (glucagon), Po0.05 vs glucagon; vs 6.8±0.3 mmol l À 1 (glucagon and GLP-1), Po0.05 vs glucagon and GLP-1; n ¼ 8-9/group; Figure 6 ).
DISCUSSION
Previous studies have shown that both naturally occurring and synthetic coagonists of the GLP-1 and glucagon receptors reduce food intake, promote weight loss and improve glucose homoeostasis in rodents. 19, 20 The coagonists are synthetic long acting peptides, which differ from the naturally occurring hormones in their pharmacokinetic and receptor binding properties. Previous studies of the anorectic effects of centrally administered GLP-1 in rats have shown differences from EX-4, which is considered a pure GLP-1R agonist, highlighting the need to study the effects of native hormones. 21 The anorectic effects of combination of native GLP-1 and glucagon have not previously been studied, and furthermore neither has the effect of anorectic doses of glucagon on neuronal activation. Addressing these points formed the basis of the current study.
Glucagon reduced food intake within the first 30 min following peripheral administration and c-fos expression was induced in the AP, cNTS, CeA and PBN. The pattern of c-fos activation seen in response to GLP-1 in the current study in mice is consistent with a previously published study in rats 22 and is similar to activation seen in response to peripherally administered glucagon in our study. Somewhat surprisingly we failed to see any difference in the neuronal activation induced by anorectic doses of GLP-1 and glucagon at the anatomical level. There may however be differences in the neuronal populations activated by GLP-1 and glucagon within any of the nuclei studied and an immunohistochemical or other characterisation of the neurons activated would help to determine whether there is in fact no difference in the pattern of neuronal activation induced by these two hormones.
In order to achieve statisitically significant increases in c-fos expression, higher doses of both GLP-1 and glucagon were required than to observe an anorectic effect. Although there appear to be differences in the sensitivity of the c-fos expression measurement and the behavioural response, overall the two measures show good coherence in the current studies.
Previous studies have shown that the anorectic effect following glucagon administration is blunted in vagotomised animals 3,15, suggesting this effect is influenced by vagal input. It has been hypothesised that glucagon acts on sensory afferents in the liver and/or gastrointestinal tract, and a glucagon satiety signal is relayed from these sites to the brain via the vagus nerve. 3 In the current study, peripherally administered glucagon induced c-fos immunoreactivity in the cNTS, which receives signals directly from the vagus nerve originating in the liver and gastrointestinal tract [23] [24] [25] and thus, is consistent with this hypothesis. However, low levels of glucagon receptor mRNA are found in the hypothalamus and brainstem in rodents 26 and, the possibility of direct glucagon action in these areas to reduce food intake remain to be investigated. Similarly, GLP-1 receptors are found in the paraventricular, arcuate, DMN and supraoptic nucleus of the hypothalamus and the AP, NTS and dorsal motor nucleus of the vagus nerve of the brainstem. 27 Vagotomy or ablation of the brainstem-hypothalamus pathways attenuates, but does not completely abolish reduction in food intake following peripheral GLP-1 administration, suggesting that peripheral effects are in part, mediated via the vagus nerve. 14, 16 We found that glucagon and GLP-1 increased c-fos activation in the PBN at high doses. Activation was seen in this nucleus in response to the GLP-1 receptor agonist exendin-4 in a previous study. 28 The PBN is known to receive extensive projections from the NTS 29 and this may be a pathway, by which high doses of GLP-1 and glucagon activated neurons in the PBN.
The CeA receives projections from both the PBN and NTS 30, 31 and c-fos expression in this nucleus is stimulated by a range of anorectic stimuli including GLP-1. 22, 32 Both GLP-1 and glucagon activated the CeA in the current studies, and in addition it appeared to be activated to a greater extent by the combined administration of GLP-1 and glucagon than the other areas examined. If it is the case that the CeA has an important part in mediating the anorectic effets of singly and coadministerred GLP-1 and glucagon, this would be consistent with the strong activation seen in this nucleus in the current studies.
It is unclear whether glucagon has a physiological role in meal termination and satiety. Infusion of antiglucagon antibodies increases meal size in rats, suggesting endogenous glucagon affects satiety. 4 Previous studies have shown that higher circulating levels of glucagon are required to inhibit food intake than are observed postprandially. 33 Such elevated circulating levels of glucagon are reached in response to a range of stressors, 34 and thus while postprandial glucagon may not be sufficient to affect feeding, it is possible that glucagon-induced anorexia forms part of the stress response. Although not assessed in this study, plasma levels of cortisol and other markers of hypothalamic-pituitary adrenal axis stimulation could be measured to elucidate this further.
Our results from coadministration of glucagon and GLP-1 are in agreement with observations by Pocai et al., 20 who demonstrated a superior anorectic effect in response to their GLP-1/glucagon receptor coagonist compared with a specific GLP-1 receptor agonist. However, the EC 50 s of their two peptides at the GLP-1 receptor were not identical, which could account for the difference in anorectic effect observed. In the current study, GLP-1 and glucagon were coadministered at doses, which individually did not significantly reduce food intake, but nevertheless produced an anorectic effect in combination. This was also reflected in significant neuronal activation in the AP and CeA following coadministration of both GLP-1 and glucagon. This suggests the possibility that concurrent activation of GLP-1 and glucagon receptors may be sufficient to activate the same neuronal pathways at lower doses of agonist than if only one receptor system is activated. However, glucagon and GLP-1 are both products of the preproglucagon gene and are structurally similar. At high doses, these peptides can demonstrate crossreactivity at each other's receptors. Therefore, it is possible that the data presented represents additive effects on a single receptor system. In conclusion the current study found first, that neurons in the brainstem and amygdala are activated by anorectic doses of glucagon, and second that the pattern of activation was indistinguishable from that of GLP-1. Further it was found that a low, subanorectic dose of glucagon can be combined with a subanorectic dose of GLP-1 to inhibit feeding. Coadministration of low doses of GLP-1 and glucagon produced more readily detectable c-fos expression in the AP and CeA than the individually administered peptides, but did not affect the pattern of activation. Finally, we also demonstrated that coadministration of glucagon and GLP-1 can prevent the acute hyperglycaemia associated with glucagon alone and in response to GLP-1 at later time points. GLP-1/glucagon receptor coagonists may therefore allow beneficial effects of glucagon, such as increased energy expenditure, to be exploited in a treatment for obesity, while maintaining a significant reduction in food intake and euglycaemia due to glucagon and GLP-1 receptor activation. Further studies are required to further investigate this possibility, but the development of such GLP-1/glucagon receptor coagonists may represent an exciting therapeutic target for novel antiobesity agents.
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